Vimarsana
Biggest News Aggregation in the World

Page 4 - Mablink Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mablink Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mablink Bioscience Today - Breaking & Trending Today

Financing roundup: Neumora refuels, Ascidian ascends, Mablink's moves & more - Vimarsana News

Financing roundup: Neumora refuels, Ascidian ascends, Mablink's moves & more

Published: October 14, 2022

Odyssey Therapeutics raised $168 million in Series B financing, the largest round of funding for a biotech startup this week. Companies developing new technologies in genetic diseases, cancer, and drug research are represented also represented in this week’s recap of life science financings.

Source: medcitynews.com
Related Topics:
United StatesGary GlickMablink BioscienceOschner HealthObatala SciencesDeerfield Management CompanyClinical Stage Neumora TherapeuticsOdyssey TherapeuticsBoston Based OdysseyAscidian TherapeuticsOchre BioUnited Kingdom BasedMatchpoint TherapeuticsAtlas VenturesAccess BiotechnologyFrance Based MablinkSofinnova PartnersSan Diego BasedManagement CompanyNew Orleans BasedVenture CapitalWeight LossMedical DevicesHealthcare InnovationMedcity News
Mablink Bioscience S.A.S.: Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy - Vimarsana News

Mablink Bioscience S.A.S.: Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy

Published: October 21, 2021

Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience's proprietary PSARlink drug-linker technology. Mablink Bioscience S.A.S. a biotechnology

Source: finanznachrichten.de
Related Topics:
Nordrhein WestfalenJean Guillaume LafayKostenloser WertpapierhandelMarc LopezMablink BioscienceMarseille UniversitHeidelberg PharmaCancer Research CenterDrug AdministrationHeidelberg Pharma ResearchHeidelberg Pharma Research GmbEmergence TherapeuticsGuillaume LafayWhile Mablink BioscienceAix Marseille UniversitHeidelberg Pharma Research GmbhKurma PartnersChief Executive OfficerExecutive Officer